Celltrion Report Results of Truxima (biosimilar, rituximab) Based Regimen in P-II Study for R/R Aggressive B-cell Lymphoma #EHA25

 Celltrion Report Results of Truxima (biosimilar, rituximab) Based Regimen in P-II Study for R/R Aggressive B-cell Lymphoma #EHA25

Celltrion Reports Results of Remsima SC (biosimilar, infliximab) in a Clinical Study for Active Crohn’s Disease and Ulcerative Colitis #ECCO2020

Shots:

  • Celltrion has presented the result of P-II study that showed that regimen of Truxima (375mg/m2) + lenalidomide (20mg, day 1-21, qd) + acalabrutinib (100mg, day 1-28, bid) (R2A) is well-tolerated and effective in relapsed/refractory aggressive B-cell lymphoma
  • In the 13 patients who underwent disease assessment following the R2A regimen, ORR (69%) and CR (31%), @6-mos. PFS (83%) and only one patient experienced disease progression after the initial objective response
  • Throughout the study, out of 22 patients, dose reduction was performed in 3 and 1 patients for lenalidomide and acalabrutinib respectively due to hematologic toxicities. The data indicate that the R2A regimen was well tolerated in Korean r/r BCL patients, with initial analysis in non-GCB DLBCL patients showing a promising response

Click here to read full press release/ article | Ref: Celltrion | Image: Celltrion

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post